why choose us

First received: December 08, 2022

Clinical Trial: Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

Study Status: Completed

Recruit Status: RECRUITING

Condition: Proliferative Glomerulonephritis With Monoclonal IgG Deposits

Study Type: INTERVENTIONAL


Official Title: A Multi-center Open-label Trial Evaluating the Efficacy and Safety of Daratumumab SC in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID)

Brief Summary: The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).

Read more